Metoprolol
-
Cytokinetics Presents MAPLE-HCM Primary Results at ESC 2025 and Publishes in NEJM
Cytokinetics’ MAPLE-HCM trial results show aficamten significantly outperformed metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). Aficamten improved exercise capacity (+1.1 mL/kg/min), while metoprolol decreased it (-1.2 mL/kg/min). 51% of aficamten patients improved in functional class, compared to 26% on metoprolol. Aficamten also showed superiority in secondary endpoints. The FDA is reviewing aficamten with a PDUFA date of December 26, 2025. A higher incidence of hypertension was noted with aficamten.